Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Protein Rescues Function After Heart Failure

This article was originally published in Start Up

Executive Summary

Impaired calcium uptake is a hallmark of heart failure. The enzyme SERCA2a is known to play a critical role in maintaining the normal contractile function of those cells whose activity is decreased or disrupted in failing hearts. But its large size makes the enzyme a difficult drug target. Now, however, a research team has identified a small protein that interacts with SERCA2a after heart failure, which could open the door on a potential new approach to therapy.

You may also be interested in...

Genetic Approaches Look Beyond Oncogenes For Cancer Therapy Targets

A half decade of large-scale cancer genome sequencing has identified only one new and relatively common druggable oncogene target. But the genes that cause out-of-control proliferation also create problems for the cancer cells, which may then need to hijack normal cellular functions to help them survive. A research team used genetic screening to find such a dependency and showed that inhibiting the process could improve treatment.

Where Are They Now? Checking In On Four Cardiovascular Start-Ups

It's no secret increasing generic competition and regulatory oversight, combined with the financial challenges of developing a primary care drug, make cardiovascular a tough place for venture-backed biotechs. START-UP takes the pulse of four previously profiled cardiovascular companies -- arca Biopharma, Celladon, NovaCardia and Portola Pharmaceuticals, -- to see what lessons they've learned.

Despite Challenges, Congestive Heart Failure Draws A Crowd

Across the industry, cardiovascular R&D budgets are shrinking, and in some cases, practically disappearing. Some large companies are de-emphasizing the cardiovascular space, citing factors ranging from the size and high expense of clinical trials to the challenge of proving benefit when most experimental therapies are tested in tandem with current standards of care. Nonetheless, for those companies still willing to venture into the cardiovascular arena, congestive heart failure (CHF) offers a huge, lucrative indication to pursue. Several start-up firms are targeting CHF and related conditions by a variety of mechanisms, including polymer therapeutics, microRNA targeting and gene therapy. In this issue, we profile four such start-ups: miRagen Therapeutics, NellOne Therapeutics, Phrixus Pharmaceuticals and Sorbent Therapeutics.

Related Companies

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts